top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

19.30 -0.33 (-1.68%)
Delayed Quote Updated: 9:55 AM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Omeros Corporation Reports Second Quarter 2026 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
From Omeros Corporation
Via Business Wire
News headline image
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
From Omeros Corporation
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
News headline image
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
News headline image
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Webcast Details for Annual Meeting of Shareholders
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports First Quarter 2026 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
From Omeros Corporation
Via Business Wire
News headline image
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces First Commercial Sales of YARTEMLEA®
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
From Omeros Corporation
Via Business Wire
News headline image
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Third Quarter 2025 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
From Omeros Corporation
Via Business Wire
News headline image
The Terrific Ten Undercard: OMER, VERI, SNYR, MYSE, RDZN – Stocks Under $5 (Complete List Inside)
Via AB Newswire
Topics Artificial Intelligence Cannabis
News headline image
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Second Quarter 2025 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
From Omeros Corporation
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page